CN103040891A - Centipeda minima volatile oil and preparation method and application thereof - Google Patents
Centipeda minima volatile oil and preparation method and application thereof Download PDFInfo
- Publication number
- CN103040891A CN103040891A CN2013100063449A CN201310006344A CN103040891A CN 103040891 A CN103040891 A CN 103040891A CN 2013100063449 A CN2013100063449 A CN 2013100063449A CN 201310006344 A CN201310006344 A CN 201310006344A CN 103040891 A CN103040891 A CN 103040891A
- Authority
- CN
- China
- Prior art keywords
- volatile oil
- centipeda
- application
- centipeda volatile
- extraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000341 volatile oil Substances 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims description 7
- 241000928504 Centipeda minima Species 0.000 title abstract 2
- 241001633683 Centipeda <firmicute> Species 0.000 claims abstract description 35
- 206010061218 Inflammation Diseases 0.000 claims abstract description 16
- 230000004054 inflammatory process Effects 0.000 claims abstract description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 15
- 238000000605 extraction Methods 0.000 claims description 15
- 239000012530 fluid Substances 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 235000019476 oil-water mixture Nutrition 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 230000003385 bacteriostatic effect Effects 0.000 abstract description 12
- 241000222122 Candida albicans Species 0.000 abstract description 8
- 241000588724 Escherichia coli Species 0.000 abstract description 8
- 229940095731 candida albicans Drugs 0.000 abstract description 8
- 241000235342 Saccharomycetes Species 0.000 abstract 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 8
- 241000194017 Streptococcus Species 0.000 description 7
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000012567 medical material Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229960002064 kanamycin sulfate Drugs 0.000 description 3
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical group COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 208000006374 Uterine Cervicitis Diseases 0.000 description 2
- 206010046914 Vaginal infection Diseases 0.000 description 2
- 201000008100 Vaginitis Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 206010008323 cervicitis Diseases 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 210000004999 sex organ Anatomy 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 208000002003 vulvitis Diseases 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides an application of centipeda minima volatile for preventing or treating gynecological inflammations. The centipeda minimav volatile oil has higher bacteriostatic activity for escherichia coli, streptococci, saccharomycetes and candida albicans, therefore the centipeda minimav volatile oil can be used for preventing or treating the gynecological inflammations.
Description
Technical field
The present invention relates to the Chinese herbal medicine extracting field, relate in particular to a kind of centipeda volatile oil and its production and use.
Background technology
Herba Centipedae is the dry herb of feverfew Herba Centipedae.The property hot, warm, return lung meridian, have dispersing wind-cold, clearing the nasal passage, the effect of cough-relieving is used for headche due to wind-cold, cough with copious phlegm, it is obstructed to have a stuffy nose, the nasal sinusitis watery nasal discharge.Now extracted from centipeda volatile oil and isolated 84 chemical constituents, identified 55 chemical constituents, recall rate is 65.5%, and wherein the content with acetic acid chrysanthene ester is the highest, can reach more than 50%.At present, the research that centipeda volatile oil is used for the treatment of gynecological inflammation not yet has the research report, for this reason, is necessary that the effect that centipeda volatile oil is used for the treatment of gynecological inflammation further studies.
Gynecological inflammation is women's common disease, mainly refers to the inflammation of female sex organ, specifically comprises female vulva inflammation, vaginitis, cervicitis, pelvic inflammatory disease etc.The Main Pathogenic Bacteria kind is escherichia coli, staphylococcus aureus, bacillus pyocyaneus, streptococcus, Candida albicans, yeast etc.
Summary of the invention
The present invention at first provides the application of a kind of centipeda volatile oil in prevention or treatment gynecological inflammation.
The present invention also provides the application of a kind of centipeda volatile oil in preparation prevention or treatment gynecological inflammation medicine.
Wherein above-mentioned centipeda volatile oil prepares by the following method: adopt supercritical CO
2Fluid extraction method extraction Herba Centipedae, extracting pressure 20-30Mpa, extraction time 1-3h, extraction temperature 30-50 ℃.
Above-mentioned centipeda volatile oil can also prepare by the following method: Herba Centipedae is added 5-15 times of water soaking, then in volatile oil extractor, extract volatile oil 2-6 hour, collect oil water mixture, extracted with diethyl ether, reclaim ether, obtain centipeda volatile oil.
Above-mentioned centipeda volatile oil has stronger bacteriostatic activity to escherichia coli, streptococcus, yeast and Candida albicans, can be used as antibacterial; The Main Pathogenic Bacteria kind of gynecological inflammation is escherichia coli, staphylococcus aureus, bacillus pyocyaneus, streptococcus, Candida albicans, yeast etc., therefore, centipeda volatile oil can be used for prevention or treatment gynecological inflammation, such as vulvitis, vaginitis, cervicitis, pelvic inflammatory disease etc., also can be used for preparing the medicine of prevention or treatment gynecological inflammation.
When centipeda volatile oil is used for prevention or treatment gynecological inflammation, can use separately, also can cooperate other pharmaceutic adjuvants to be made into suppository, tablet etc., also can be with the use of other drug compatibility etc.The consumption of centipeda volatile oil when being used for prevention or treatment gynecological inflammation is 0.0001-1000mg/Kg, and preferred consumption is 0.001-100mg/Kg, and further preferred consumption is 0.01-10mg/Kg.
The specific embodiment
Supercritical CO
2Fluid extraction instrument: be purchased from Haian Oil Scientific Research Apparatus Co., Ltd., model: HA221-50-06
Herba Centipedae: be purchased from Changchun grand inspection medical material company, lot number 110604
Kanamycin sulfate: it is biological to be purchased from U.S.'s Baeyer enlightening, product article No. 1758-9316
Methyl hydroxybenzoate: be purchased from Beijing and win China and rise Science and Technology Ltd., lot number: 99-76-3
Escherichia coli: ATCC8739
Streptococcus: ATCC19615
Yeast: ATCC10231
Candida albicans: ATCC90029
Embodiment 1
The preparation of centipeda volatile oil: take by weighing Herba Centipedae medical material 500g, adopt supercritical CO
2The fluid extraction instrument extracts volatile oil, extracting pressure 20Mpa, and extraction time 2h, 40 ℃ of extraction temperature obtain centipeda volatile oil 9.8ml.
Embodiment 2
The preparation of centipeda volatile oil: take by weighing Herba Centipedae medical material 500g, add 10 times of water soakings and spend the night, extract volatile oil 4h in volatile oil extractor, collect oil-water mixture, extracted with diethyl ether reclaims ether, obtains centipeda volatile oil 0.8ml.
Embodiment 3
The preparation of centipeda volatile oil: take by weighing Herba Centipedae medical material 500g, adopt supercritical CO
2The fluid extraction instrument extracts volatile oil, extracting pressure 25Mpa, and extraction time 1.5h, 45 ℃ of extraction temperature obtain centipeda volatile oil 7.2ml.
The research of embodiment 4 centipeda volatile oil In Vitro Bacteriostatics
For trying strain:
Escherichia coli (ATCC8739), streptococcus (ATCC19615), yeast (ATCC10231), Candida albicans (ATCC90029), Institute of Microorganism, Academia Sinica.
Culture medium:
(1) beef-protein medium: Carnis Bovis seu Bubali cream 3g, peptone 10g, NaCl5g, agar 1.5%-2.0% (fluid medium does not contain agar), water 1000mL, pH7.0-7.2 (using the NaOH solution of 1.0mol/L to regulate pH).
(2) YPD culture medium: yeast soaks powder 10g, peptone 20g, glucose 20g, agar 1.5%-2.0% (fluid medium does not contain agar), water 1000mL, natural pH value.
The preparation of bacteria suspension:
Be inoculated in the corresponding fluid medium from the one ring thalline of picking on the thalline inclined-plane of overactivation, put into constant-temperature shaking incubator and be cultured to exponential phase.Draw respectively the confession examination bacterium liquid 0.5mL of above incubation time, add sterilized water doubling dilution to 10
5-10
6ML
-1, for subsequent use.
Supply the reagent thing:
Contrast medicine: kanamycin sulfate (mass concentration is 6g/L), methyl hydroxybenzoate (mass concentration is 40g/L).
The centipeda volatile oil of investigational agent: embodiment 1
The mensuration of bacteriostatic activity:
Adopt the filter paper method to measure bacteriostatic activity.Use card punch, qualitative filter paper is made the roundlet scraps of paper (D=6mm), for subsequent use behind the autoclaving.Under the aseptic condition, the culture medium 25.00mL of the corresponding strain of impouring in sterilized culture dish makes solid plate after the cooled and solidified.Draw the bacteria suspension 200 μ L that prepared and join in the corresponding solid plate culture medium, utilize spreading rod with the coating of bacterium liquid evenly.Getting filter paper is attached to and contains on the bacterium flat board, on every filter paper, drip respectively 10 μ L(centipeda volatile oil low dose group), dosage group in the 20 μ L(centipeda volatile oils), 30 μ L(centipeda volatile oil high dose group) centipeda volatile oil, kanamycin sulfate 15 μ L and methyl hydroxybenzoate 20 μ L, every ware pastes 3, notes during subsides will maintaining a certain distance between the filter paper.Place 37 ℃ of incubators to cultivate 24h escherichia coli, streptococcus, Candida albicans, yeast places 30 ℃ of incubators to cultivate 48h.Choose the obvious plane-table operation diameter of inhibition zone after cultivating end, the result gets the meansigma methods of repeated trials.
Result and conclusion:
The basic, normal, high dosage group of centipeda volatile oil, kanamycin sulfate group and methyl hydroxybenzoate group are as shown in table 1 for the Antibacterial Activity result of examination strain to 4 strains.
Table 1 trial drug is to the bacteriostatic activity for the examination strain
Annotate: with high dose group ratio, #P 0.05, with kanamycin sulfate group ratio, * P〉0.05, with methyl hydroxybenzoate group ratio, ▲ P＜0.05
As shown in Table 1, the centipeda volatile oil of embodiment 1 all has stronger bacteriostatic activity to escherichia coli, streptococcus, Candida albicans and yeast, and the strongest to colibacillary bacteriostatic activity.Middle dosage group compares bacteriostatic activity and the high dose group of 4 strains for the examination strain, no difference of science of statistics (P〉0.05), middle dosage group compares bacteriostatic activity and the kanamycin sulfate group of 4 strains for the examination strain, no difference of science of statistics (P〉0.05), middle dosage group compares bacteriostatic activity and the methyl hydroxybenzoate group of 4 strains for the examination strain, variant (P＜0.05) is better than methyl hydroxybenzoate to 4 strains for the bacteriostatic activity that tries strain.
Claims (4)
1. the application of centipeda volatile oil in prevention or treatment gynecological inflammation.
2. the application of centipeda volatile oil in preparation prevention or treatment gynecological inflammation medicine.
3. application according to claim 1 and 2 is characterized in that described centipeda volatile oil prepares by the following method: adopt supercritical CO
2Fluid extraction method extraction Herba Centipedae, extracting pressure 20-30Mpa, extraction time 1-3h, extraction temperature 30-50 ℃.
4. application according to claim 1 and 2, it is characterized in that described centipeda volatile oil prepares by the following method: Herba Centipedae is added 5-15 times of water soaking, then in volatile oil extractor, extracted volatile oil 2-6 hour, collect oil water mixture, extracted with diethyl ether, reclaim ether, obtain centipeda volatile oil.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013100063449A CN103040891A (en) | 2013-01-08 | 2013-01-08 | Centipeda minima volatile oil and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013100063449A CN103040891A (en) | 2013-01-08 | 2013-01-08 | Centipeda minima volatile oil and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103040891A true CN103040891A (en) | 2013-04-17 |
Family
ID=48053902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013100063449A Pending CN103040891A (en) | 2013-01-08 | 2013-01-08 | Centipeda minima volatile oil and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103040891A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103858764A (en) * | 2014-03-19 | 2014-06-18 | 钦州市林业科学研究所 | Centipeda minima tissue culture rapid propagation medium and centipeda minima one-time seedling formation tissue culture rapid propagation method |
| CN104857049A (en) * | 2015-04-23 | 2015-08-26 | 李应英 | Preparation method of medicine to treat liver cirrhosis ascites |
-
2013
- 2013-01-08 CN CN2013100063449A patent/CN103040891A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| 李雪萍等: "李学声名老中医独药外治阴道炎经验", 《中医外治杂志》 * |
| 覃仁安等: "鹅不食草挥发油抗炎作用及机制研究", 《中国医院药学杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103858764A (en) * | 2014-03-19 | 2014-06-18 | 钦州市林业科学研究所 | Centipeda minima tissue culture rapid propagation medium and centipeda minima one-time seedling formation tissue culture rapid propagation method |
| CN103858764B (en) * | 2014-03-19 | 2015-07-08 | 钦州市林业科学研究所 | Centipeda minima tissue culture rapid propagation medium and centipeda minima one-time seedling formation tissue culture rapid propagation method |
| CN104857049A (en) * | 2015-04-23 | 2015-08-26 | 李应英 | Preparation method of medicine to treat liver cirrhosis ascites |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102631379B (en) | Preparation method of taxus chinensis active extract and application thereof in fungus resistance | |
| CN105193876A (en) | Purslane extract and preparation method thereof | |
| WO2011035734A1 (en) | Relinqing extract, preparative method and use thereof | |
| CN102793881A (en) | Traditional Chinese medicine gel for treating vaginitis as well as preparation method and application of traditional Chinese medicine gel | |
| Saeidi et al. | Effects of Rosmarinus officinalis plant extract on Trichomonas vaginalis parasites and Candida albicans under laboratory conditions: an experimental study | |
| CN103040891A (en) | Centipeda minima volatile oil and preparation method and application thereof | |
| CN103735864B (en) | A kind of clinical laboratory antibacterial | |
| Kovalev et al. | Antimicrobial activity of extracts of Iris hungarica and Iris sibirica | |
| CN102451221A (en) | Astragalus polysaccharides microecological regulator | |
| CN102727550B (en) | Antifungal artemisia argyi rhizome leavening and preparation technology thereof | |
| CN110638985A (en) | Chinese medicinal composition gel suppository for treating gynecological inflammation and preparation method thereof | |
| CN102743432B (en) | Application of patchouli oil in preparation of medicines used for treating colpitis | |
| CN108210538A (en) | A kind of chamomile hydrosol extracting method of anti-candida albicans | |
| CN103638055B (en) | Polyhachis vicina Roger extract and and antifungal pharmaceutical purposes thereof | |
| CN101757140B (en) | Medicament with spermicidal effect in vitro and bacteriostatic action, and preparation method and application thereof | |
| CN107412344B (en) | Pharmaceutical composition for treating pet skin diseases and preparation method thereof | |
| CN103211920B (en) | Callicarpa kwangtungensis chun. low-polarity ingredient extract, pharmaceutical composition containing Callicarpa kwangtungensis chun. low-polarity ingredient extract, preparation method and application | |
| CN101123974A (en) | Silver-ionized plant extraction liquid and use thereof | |
| CN104996472A (en) | Bactericide for sterilizing operating room | |
| CN104840701A (en) | Gel for treating vaginitis | |
| CN104857116A (en) | Applications of traditional Chinese medicine sanguisorba officinalis in preparing antifungal drug synergist | |
| CN102727599B (en) | Trollius chinensis dreg fermented product with antifungal effect and process for preparing trollius chinensis dreg fermented product | |
| CN102641314A (en) | Medicine composition for preventing and/or treating gynecological diseases | |
| CN102168035A (en) | Streptomyces hawaii and application thereof | |
| CN106265861A (en) | Antifungal composition containing Chinese mugwort ash and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: YANG YANLING Free format text: FORMER OWNER: SHIHUIDA PHARMA GROUP (JILIN) CO., LTD. Effective date: 20130930 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20130930 Address after: 200439 Shanghai city Baoshan District Gaoyi Road No. 105 6 floor Applicant after: Yang Yanling Address before: 200439 Shanghai city Baoshan District Gaoyi Road No. 105 Yixian building 6 floor Applicant before: Shihuida Pharma Group (Jilin) Co., Ltd. |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130417 |